Dr. Mark Truty

Mayo Clinic researchers identify a measurable genetic mutation as a significant predictor of metastasis and survival in pancreatic cancer

The presence of a specific genetic mutation — KRAS circulating tumor DNA (ctDNA) — strongly indicates a higher risk of spread and worse survival rates for people with pancreatic cancer.

Beyond the Code: Advancing early pancreatic cancer diagnoses

Mayo Clinic pancreatic cancer experts highlight the importance of early diagnosis and the role of artificial intelligence in transforming patient outcomes.

Looking back on pancreatic cancer, 5 years later

Rita Krueger shares the lessons she has learned from her experience with pancreatic cancer diagnosis, treatment and survivorship.

5 cosas que debe saber sobre el cáncer de páncreas

La tasa de supervivencia a cinco años para el cáncer de páncreas es solo del 10,8 %. Aquí hay cinco cosas que todos deberían saber sobre este cáncer mortal.

PET/MRI biomarkers guide personalized treatment for people with pancreatic cancer, study finds

A recent study provides support for Mayo Clinic's use of positron emission tomography (PET) to guide pancreatic cancer treatment decisions.

5 things to know about pancreatic cancer

The five-year survival rate for pancreatic cancer is just 10.8%. Here are five things everyone should know about this deadly cancer.